{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"INTerpath-014","nct_id":"NCT07513376","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-014-nct07513376. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"INTerpath-014","arms":[{"description":"Participants will receive intismeran 1 mg via intramuscular (IM) injection plus pembrolizumab coformulated with berahyaluronidase alfa 790 mg via subcutaneous (SC) injection.","label":"Arm A: Intismeran + Pembrolizumab with Berahyaluronidase Alfa","type":"EXPERIMENTAL"},{"description":"Participants will receive intismeran 1 mg via IM injection.","label":"Arm B: Intismeran","type":"EXPERIMENTAL"},{"description":"Participants will receive dose-matched placebo via IM injection.","label":"Arm C: Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2038-05-11","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":876,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intismeran","otherNames":["V940","mRNA-4157"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab coformulated with berahyaluronidase alfa","otherNames":["MK-3475A"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-19","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2034-08-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C","timeFrame":"Up to approximately 98 months"}],"references":[],"start_date":{"date":"2026-05-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)","url":"https://clinicaltrials.gov/study/NCT07513376"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-014-nct07513376"}